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Introduction
A revised definition of pulmonary hypertension (PH) was proposed in 2018 by a task force at the 6th World Symposium on Pulmonary Hypertension, stating that the mean pulmonary arterial pressure (mPAP) threshold by which PH is defined during right heart catheterization (RHC) should be lowered from 25 mmHg at rest to >20 mmHg at rest 1 ( Table 1) . This proposed change recognizes that the >25 mmHg threshold defined at the 1st World Symposium on Pulmonary Hypertension in 1973, and updated to 25 mmHg in 2009, 4 was an arbitrary threshold, 5 conservatively chosen to prevent overdiagnosis and overtreatment. 1 In contrast, the >20 mmHg threshold is supported by scientific evidence. A systematic review of all available data from RHC studies in healthy individuals defined a normal mPAP (mean 6 SD) at rest as 14.0 6 3.3 mmHg. 6 If the upper limit of normal is regarded as the mean value þ2 SDs, an mPAP >20 mmHg should be considered to be above normal. 6 PH is classified into five groups, according to similar clinical characteristics, underlying causes and treatment strategies, 2,3 and the revision to the mPAP threshold is proposed for all clinical groups of PH.
The revised definition incorporates inclusion of pulmonary vascular resistance (PVR) 3 Wood units (WU) in the definition of all forms of pre-capillary PH (Groups 1, 3, 4, and 5) ( Table 1) . 1 Despite a lack of definitive proof that PVR is a marker of pulmonary vascular disease, the revised definition acknowledges that to attribute an mPAP >20 mmHg to pulmonary vascular disease, and to differentiate pre-capillary PH from post-capillary PH, PVR in combination with pulmonary arterial wedge pressure is the best criterion available. 1 The pros and cons of the proposed revision to the definition of PH have been debated in the literature. 7, 8 In our opinion, the proposed threshold of an mPAP of >20 mmHg is the correct threshold to use for defining PH, and the greater emphasis given to elevated PVR for detecting pulmonary vascular disease is a necessary paradigm shift. The clinical justification for the suggested change has been described in detail elsewhere, 1,7 yet as the proposal is relatively recent and has not yet been adopted in clinical practice, there are limited data on how it will affect clinical management. Therefore, in this article, we will discuss the potential effect of this revised definition on patient management, based on our clinical experience.
The impact of the revised definition of pulmonary hypertension on patient management
We predict that the main impact of the new PH definition on patient management will be earlier identification of PH. If patients with abnormal elevation in mPAP (>20 mmHg) are identified when they have an mPAP within the range of 21-24 mmHg, i.e. at an earlier stage of disease than patients with an mPAP 25 mmHg, they can be closely monitored and recommended treatment can begin as soon as clinically indicated. There is accumulating evidence that an abnormal mPAP that is elevated but below 25 mmHg is associated with increased risk of morbidity, mortality and progression to symptomatic PH 9-11 compared with a normal mPAP. An elevated mPAP of 21-24 mmHg has been identified in several patient groups at risk of developing PH, such as those with lung disease, left heart disease, or connective tissue disease 12 and is predictive of progression to an mPAP of 25 mmHg in patients with systemic sclerosis. 13, 14 
Group 1 pulmonary hypertension [pulmonary arterial hypertension]
As the initial symptoms of PH are non-specific, diagnosis is often only confirmed when the disease is already advanced. 15 Therefore, earlier diagnosis of PH, when mPAP is within the 21-24 mmHg range, is only likely to be feasible in patient populations known to be at high risk of PH who can be closely monitored in screening programmes for early signs of PH development. 2, 3 In practice, this is likely to apply predominantly to patients with pulmonary arterial hypertension (PAH) (Group 1 of the clinical classification of PH), for example systemic sclerosis patients and subjects with mutations associated with PAH. As systematic screening programmes are already in use to identify patients at risk of developing PAH among these populations, these screening programmes may allow identification of patients with an elevated mPAP of 21-24 mmHg. 16 For example, for systemic sclerosis patients, the DETECT screening algorithm uses six widely available assessments to determine the need for echocardiography referral, and subsequently two echocardiographic variables to determine the need for RHC to identify PAH. 17 When applying the DETECT algorithm in a single centre in Norway, 31% of systemic sclerosis patients undergoing RHC to diagnose suspected PAH had an elevated mPAP of 20-24 mmHg. In contrast, before DETECT was introduced, only 17% of patients undergoing RHC had an mPAP of 20-24 mmHg. 16 Patients who are carriers of mutations associated with PAH, such as the BMPR2 gene mutations, are another The revised definition of pulmonary hypertension K5 population at high risk of developing PAH. 18 At the time of their diagnosis, patients with PAH who have BMPR2 mutations tend to be younger, with more severe disease and a greater risk of death than those without BMPR2 mutations. 19 Screening of patients with a familial PAHcausing genetic mutation is recommended by the European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines, 2,3 and asymptomatic carriers of BMPR2 mutations are already offered inclusion in clinical screening programmes in some centres. 18 Research is underway to determine the optimal screening strategies to identify development of PAH in patients with BMPR2 mutations. 20 Although we anticipate that the revised definition will enable earlier diagnosis for some PAH patients, this does not imply that treatments currently approved for PAH are also appropriate for these patients. While it is accepted that early treatment is beneficial in PAH patients with an mPAP 25 mmHg, 21 the management of patients with an mPAP of 21-24 mmHg has not been widely examined. 2, 3 Based on the previous definition of PAH, the inclusion criteria for clinical trials investigating PH therapies typically stipulated that only patients with an mPAP 25 mmHg are included. To date, only two small studies investigating PH therapies in patients with a resting mPAP <25 mmHg have been completed, both in the setting of systemic sclerosis 22, 23 and only a small number of ongoing studies are enrolling patients with an mPAP of 21-24 mmHg. 24,25 Greater inclusion of patients with an mPAP of 21-24 mmHg in prospective trials of PAH therapies is required to gain further insight into their natural history and to determine the potential benefits of different management options. The proposed revision to the definition of PAH could address this need, enabling enrolment of this population in a greater number of clinical trials by bringing them within the standard PAH definition.
Other pulmonary hypertension groups
Looking beyond patients with PAH (Group 1 of the clinical classification of PH), the revised definition is not expected to have an immediate impact on patient management for other PH groups. In the case of PAH, clinical trials can be performed to confirm whether the PH-targeted treatment options available for patients with mPAP 25 mmHg are also effective in patients with mPAP 21-24 mmHg. In contrast, for patients with PH due to left heart disease or lung disease (Groups 2 and 3, respectively), such studies cannot be performed as there are currently no recommended treatment options available for these conditions. 2,3 For patients with Group 4 PH [chronic thromboembolic PH (CTEPH)], the lower mPAP threshold in the revised definition may lead to some patients who are classified based on the previous definition as having chronic thromboembolic disease without PH (CTED) being reclassified as having CTEPH. 26, 27 As pulmonary endarterectomy-the goldstandard treatment recommended for operable CTEPH 2,3is also a beneficial treatment for operable CTED patients, 27, 28 the revised definition is not expected to change the management of these patients.
Future perspectives
As discussed, we expect that the main impact of a lower mPAP threshold in the revised definition of PH will be the detection of PAH at an earlier disease stage in some patient groups, such as systemic sclerosis patients and patients with PAH-causing genetic mutations. Elsewhere in this series of review articles, Kiely et al. 15 discuss that several new screening approaches are currently being evaluated in PH, including non-invasive approaches such as imaging, cardiopulmonary function testing, and clinical biomarkers. 15 In the future, we anticipate that combining a lower mPAP threshold with improvements in screening methods, and the development of novel screening techniques for use in patients at risk of PH, will aid earlier disease identification. If evidence is generated to support the use of PH-targeted therapies in patients with mPAP 21-24 mmHg, earlier treatment can be initiated with the aim of improving outcomes. An open question requiring future study is whether or not the pulmonary arterial wedge pressure and PVR thresholds used to define pre-capillary PH also warrant revision. These were not amended in the revised definition of PH, remaining at their previous values (PVR 3 WU and pulmonary arterial wedge pressure 15 mmHg), 1-3 however, there is ongoing discussion around whether these thresholds could be lowered. 1, 8 Summary Based on the available evidence, we believe that an mPAP of >20 mmHg is the correct threshold to use for defining PH. This threshold should be considered as a biomarker of an abnormal state of the pulmonary circulation (i.e. PH) rather than used to characterize a disease. An mPAP of >20 mmHg requires further haemodynamic characterization to identify the cause of the elevated mPAP and thus the type of PH, e.g. measurement of pulmonary arterial wedge pressure and PVR to distinguish between precapillary and post-capillary PH. The revised PH definition includes PVR in the diagnosis of all forms of pre-capillary PH, rather than just for PAH as per the previous definition, and thus emphasizes the importance of PVR for detecting pulmonary vascular disease ( Table 1) .
In terms of patient management, we anticipate that the main impact of the updated definition of PH will be to allow the identification of PH at earlier disease stages, particularly in patients at risk of PH who are already closely monitored in screening programmes, e.g. those with systemic sclerosis or PAH-causing genetic mutations. If PH is identified at an early stage, patients can be closely observed so that recommended treatment can begin as soon as it is clinically indicated.
To date, patients with an mPAP of 21-24 mmHg have generally been excluded from clinical trials and consequently there is little information on whether PH therapies are appropriate for use in these patients or on how best to manage their disease. We predict that the revised definition of PH will likely lead to a greater number of clinical trials K6 G. Simonneau and M.M. Hoeper enrolling patients with an mPAP in the 21-24 mmHg range, thereby providing valuable insight into appropriate management strategies in this population and improved characterization of the natural history and epidemiology of this patient group. We hope that clinical studies in patients with an mPAP of 21-24 mmHg will eventually lead to evidence-based treatment recommendations and, ultimately, an improved outlook for this understudied group of patients.
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